![]() Omeros Omeros Corporation is a biopharmaceutical company developing products focused on inflammation and central nervous system disorders as well as immune-related diseases, including cancers. | ![]() Alnylam Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments. | ![]() Olpha Olpha (formerly known as Olainfarm) is a company engaged in the development and manufacture of pharmaceutical products. | |
Founding Date | Founding Date 1994 | Founding Date 2002 | Founding Date 1972 |
Type | Type Public | Type Public | Type Private |
Tags | |||
Locations | Locations Seattle, US HQ | Locations Olaine, LV HQ | |
Employees | Employees 1968% decrease | Employees 1,32324% increase | Employees 2,191 |
Valuation ($) | Valuation ($) 248.6 m | Valuation ($) 36.5 b | Valuation ($) N/A |
Financial | |||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $3.7b (FY, 2025) | Revenue (est.) €122.2m (FY, 2020) |
Cost of goods | Cost of goods N/A | Cost of goods $677.2m (FY, 2025) | Cost of goods €44.5m (FY, 2020) |
Gross profit | Gross profit N/A | Gross profit $3b (FY, 2025) | Gross profit €80.1m (FY, 2020) |
Net income | Net income ($3.4m) (FY, 2025) | Net income $313.7m (FY, 2025) | Net income €9.5m (FY, 2020) |
Funding | |||
Total funding raised | Total funding raised $ 354.8m | Total funding raised $ 1.5b | Total funding raised N/A |

Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments.
View company
Olpha (formerly known as Olainfarm) is a company engaged in the development and manufacture of pharmaceutical products.
View company